Milsch L, et al. - Researchers ascertained if immune-checkpoint blocker (ICB) was active in an unselected cohort of treated patients with known brain metastases and whether disease control correlates with survival. Between 2005 and 2017, 385 subjects with metastatic malignant melanoma treated with ICB as monotherapy in two tertiary referral centers were involved. In both subjects with or without melanoma brain metastases, extracranial disease control was the dominant prognostic factor for overall survival (OS). Clinical trials in melanoma subjects with brain metastases should address end-points like symptom control, quality of life or OS in addition to intracranial response rates.